Cargando…

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Sutimlimab, a first-in-class humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively inhibits the classical complement pathway at C1s, rapidly halted hemolysis in the single-arm CARDINAL study in recently transfused patients with cold agglutinin disease (CAD). CADENZA was a 26-week r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Röth, Alexander, Berentsen, Sigbjørn, Barcellini, Wilma, D’Sa, Shirley, Jilma, Bernd, Michel, Marc, Weitz, Ilene C., Yamaguchi, Masaki, Nishimura, Jun-ichi, Vos, Josephine M. I., Storek, Michael, Wong, Nancy, Patel, Parija, Jiang, Xiaoyu, Vagge, Deepthi S., Wardęcki, Marek, Shafer, Frank, Lee, Michelle, Broome, Catherine M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437710/ https://www.ncbi.nlm.nih.gov/pubmed/35687757 http://dx.doi.org/10.1182/blood.2021014955

Ejemplares similares

P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY
por: Röth, Alexander, et al.
Publicado: (2023)

Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up
por: Röth, Alexander, et al.
Publicado: (2023)

P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK OFF-TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA STUDY
por: Röth, Alexander, et al.
Publicado: (2023)

P1486: SERUM BIOMARKERS AS PREDICTORS OF RESPONSE TO SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): A POST-HOC ANALYSIS OF PHASE 3 CARDINAL AND CADENZA STUDY DATA
por: Barcellini, Wilma, et al.
Publicado: (2023)

P1675: SUTIMLIMAB PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH COLD AGGLUTININ DISEASE: OPEN-LABEL EXTENSION OF THE PHASE 3 CADENZA STUDY
por: Röth, Alexander, et al.
Publicado: (2023)

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results
por: Röth, Alexander, et al.
Publicado: (2022)

Concomitant Use of Sutimlimab and COVID-19 Vaccines in Patients with Cold Agglutinin Disease from the Phase 3 Cardinal and Cadenza Studies
por: Fattizzo, Bruno, et al.
Publicado: (2022)

P1487: CONCOMITANT USE OF SUTIMLIMAB AND COVID-19 VACCINES IN PATIENTS WITH COLD AGGLUTININ DISEASE FROM THE PHASE 3 CARDINAL AND CADENZA STUDIES
por: Fattizzo, Bruno, et al.
Publicado: (2023)

Sutimlimab for the Treatment of Cold Agglutinin Disease
por: Berentsen, Sigbjørn
Publicado: (2023)

P1538: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK WASHOUT PERIOD IN PHASE 3 CARDINAL STUDY (NCT03347396)
por: Röth, A., et al.
Publicado: (2022)

Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
por: Röth, Alexander, et al.
Publicado: (2022)

P1532: SUTIMLIMAB AFTER PRIOR RITUXIMAB USE IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): POOLED POST-HOC ANALYSES FROM THE CARDINAL AND CADENZA TRIALS
por: Röth, A., et al.
Publicado: (2022)

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Cold agglutinin disease: current challenges and future prospects
por: Berentsen, Sigbjørn, et al.
Publicado: (2019)

New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
por: Berentsen, Sigbjørn
Publicado: (2020)

The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?
por: Berentsen, Sigbjørn, et al.
Publicado: (2023)

Mortality in cold agglutinin disease shows seasonal pattern
por: Hansen, Dennis Lund, et al.
Publicado: (2022)

Primary chronic cold agglutinin disease: An update on pathogenesis, clinical features and therapy
por: Berentsen, Sigbjørn, et al.
Publicado: (2007)

Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence?
por: Sefland, Øystein, et al.
Publicado: (2019)

Cadenzas to the piano concertos /
por: Beethoven, Ludwig van, 1770-1827
Publicado: (1979)

The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease
por: Ay, Cihan, et al.
Publicado: (2022)

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia
por: Broome, Catherine M., et al.
Publicado: (2022)

Complete transcriptions, cadenzas and exercises : for solo piano
por: Brahms, Johannes, 1833-1897
Publicado: (1971)

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A
por: Ay, Cihan, et al.
Publicado: (2023)

A Rondelay (Without Cadenza) By The Virion Of Influenza
por: Kilbourne, Edwin D.
Publicado: (2008)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study
por: Fattizzo, Bruno, et al.
Publicado: (2020)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

PB2549: CO-EXISTENT COLD AGGLUTININ DISEASE AND CRYOGLOBULINAEMIA
por: Japzon, Nicole, et al.
Publicado: (2023)

The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease
por: Zaninoni, Anna, et al.
Publicado: (2021)

A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway
por: Bartko, Johann, et al.
Publicado: (2018)

Mozart cadenzas : For flute concerto no. 1 in G major (K.V.313) and flute concerto no. 2 in D major (K.V.314) and andante in C major (K.V.315) ; also includes Three songs by Hamm and Distant voices by Lemmoné

Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia
por: Ujjani, Chaitra, et al.
Publicado: (2022)

C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia
por: de Boer, Esther C. W., et al.
Publicado: (2023)

Accurate staging of reproduction development in Cadenza wheat by non-destructive spike analysis
por: Fernández-Gómez, José, et al.
Publicado: (2020)

Role of Complement in Autoimmune Hemolytic Anemia
por: Berentsen, Sigbjørn
Publicado: (2015)

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation
por: Penter, Livius, et al.
Publicado: (2021)

Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States
por: Broome, Catherine M., et al.
Publicado: (2022)

Epidemic Keratoconjunctivitis-Causing Adenoviruses Induce MUC16 Ectodomain Release To Infect Ocular Surface Epithelial Cells
por: Menon, Balaraj B., et al.
Publicado: (2016)

High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya
por: McAuley, Charlotte F., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_mgc9c12ikh6rt7b7uhhba367ff